Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

Future Oncology

Volumn 7, Issue 10, 2011, Pages 1149-1167

  Zhou, Qian ^a   Lui, Vivian W Y ^b   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

combined targeting; hepatocellular carcinoma; PI3K Akt mTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AFINITO; AZD 8055; BKM 120; CAL 101; COLCHICINE; DOCETAXEL; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; TAXANE DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE; WORTMANNIN; XL 147;

CANCER SURVIVAL; DRUG MECHANISM; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 80054113770     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.95     Document Type: Review

References (209)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5), S5-S16 (2004). (Pubitemid 39423365)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J. Clin. Oncol. 27(9), 1485-1491 (2009).
4. Yang L, Parkin DM, Ferlay J, Li LA, Chen YD. Estimates of cancer incidence in China for 2000 and projections for 2005 Cancer Epidemiol. Biomarkers Prev. 14(1), 243-250 (2005). (Pubitemid 40165308)
5. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 353(9160), 1253-1257 (1999). (Pubitemid 29168472)
6. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14(27), 4300-4308 (2008).
7. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 13(9), S169-S171 (2002).
8. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22(33), 5093-5107 (2003). (Pubitemid 37059591)
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006). (Pubitemid 44307383)
10. De Mitri MS, Cassini R, Morsica G et al. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma. J. Viral Hepat. 13(9), 574-581 (2006).
11. Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and hepatitis C virus-infection and risk of hepatocellular-carcinoma in cirrhosis - a prospective-study. Cancer 74(9), 2442-2448 (1994). (Pubitemid 24320846)
12. Fargion S, Fracanzani AL, Piperno A et al. Prognostic factors for hepatocellular-carcinoma in genetic hemochromatosis. Hepatology 20(6), 1426-1431 (1994). (Pubitemid 24359051)
13. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis. Similar incidence to that in hepatitis C virus-related cirrhosis. Am. J. Gastroenterol. 96(4), 1160-1163 (2001). (Pubitemid 32319154)
14. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127(5), 1372-1380 (2004). (Pubitemid 39457763)
15. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the united states between 1987 and 2001: 5 year survival has improved significantly with time. J. Clin. Oncol. 21(23), 4329-4335 (2003). (Pubitemid 46621808)
16. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular-carcinoma. Hepatology 16(2), 353-357 (1992).
17. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734-1739 (2002). (Pubitemid 34607087)
18. Lo CM, Ngan H, Tso Wk et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164-1171 (2002). (Pubitemid 34454013)
19. Cardenes HR, Price TR, Perkins SM et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin. Transl Oncol. 12(3), 218-225 (2010).
20. Krishnan S, Dawson LA, Seong J et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann. Surg. Oncol. 15(4), 1015-1024 (2008).
21. Gish RG, Porta C, Lazar L et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J. Clin. Oncol. 25(28), 4512-4512 (2007).
22. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the eastern cooperative oncology group's study e1203 J. Clin. Oncol. 24(18), 4143 (2006).
23. Ramanathan RK, Belani CP, Singh DA et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A california consortium (CCC-p) trial. J. Clin. Oncol. 24(18), 4010 (2006).
24. Yeo W, Mok TS, Zee B et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon a 2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97(20), 1532-1538 (2005). (Pubitemid 41631953)
25. Endicott JA, Ling V. The biochemistry of P glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem. 58, 137-171 (1989).
26. Ng IOL, Liu CL, Fan ST, Ng M. Expression of P glycoprotein in hepatocellular carcinoma - a determinant of chemotherapy response. Am. J. Clin. Pathol. 113(3), 355-363 (2000). (Pubitemid 30217382)
27. Park JG, Lee SK, Hong IG et al. MDR1 gene-expression - its effect on drug-resistance to doxorubicin in human hepatocellular-carcinoma cell-lines. J. Natl Cancer Inst. 86(9), 700-705 (1994).
28. Faried LS, Faried A, Kanuma T et al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of caski cells to paclitaxel. Eur. J. Cancer 42(7), 934-947 (2006).
29. VanderWeele DJ, Zhou RX, Rudin CM. AKT up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol. Cancer Ther. 3(12), 1605-1613 (2004). (Pubitemid 40136716)
30. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
31. Cheng AL, Kang YK, Chen ZD et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
32. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic-variation of p53 mutational profile in nonmalignant human liver. Science 264(5163), 1317-1319 (1994). (Pubitemid 24219080)
33. Hosono S, Chou MJ, Lee CS, Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene 8(2), 491-496 (1993). (Pubitemid 23073766)
34. Minouchi K, Kaneko S, Kobayashi K. Mutation of p53 gene in regenerative nodules in cirrhotic liver. J. Hepatol. 37(2), 231-239 (2002). (Pubitemid 34833085)
35. Nose H, Imazeki F, Ohto M, Omata M. P53 gene-mutations and 17p allelic deletions in hepatocellular-carcinoma from Japan. Cancer 72(2), 355-360 (1993). (Pubitemid 23193438)
36. Edamoto Y, Hara A, Biernat W et al. Alterations of rb1, p53 and wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 106(3), 334-341 (2003). (Pubitemid 36870393)
37. Ishizaki Y, Ikeda S, Fujimori M et al. Immunohistochemical analysis and mutational analyses of b catenin, axin family and APC genes in hepatocellular carcinomas. Int. J. Oncol. 24(5), 1077-1083 (2004).
38. Ito Y, Takeda T, Sakon M et al. Expression and clinical significance of Erb B receptor family in hepatocellular carcinoma. Br. J. Cancer 84(10), 1377-1383 (2001). (Pubitemid 32522107)
39. Santoni-Rugiu E, Jensen MR, Factor VM, Thorgeirsson SS. Acceleration of c Myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF) a in transgenic mice is associated with TGF b1 signaling disruption. Am. J. Pathol. 154(6), 1693-1700 (1999). (Pubitemid 29262851)
40. Daveau M, Scotte M, Francois A et al. Hepatocyte growth factor, transforming growth factor a, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinog. 36(3), 130-141 (2003). (Pubitemid 36314790)
41. Wang R, Ferrell DL, Faouzi S, Maher JJ, Bishop JM. Activation of the met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153(5), 1023-1033 (2001). (Pubitemid 34289241)
42. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan JB, Lian ZR. Genetic mechanisms of hepatocarcinogenesis. Oncogene 21(16), 2593-2604 (2002). (Pubitemid 34438112)
43. Kubo T, Yamamoto J, Shikauchi Y, Niwa Y, Matsubara K, Yoshikawa H. Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and induces apoptosis in human hepatocellular carcinoma. Cancer Res. 64(15), 5172-5177 (2004). (Pubitemid 39006535)
44. Maeta Y, Shiota G, Okano J, Murawaki Y. Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells. Tumor Biol. 26(6), 300-305 (2005). (Pubitemid 41619460)
45. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. P16(ink4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116(2), 394-400 (1999). (Pubitemid 29055363)
46. Murata H, Tsuji S, Tsujii M et al. Promoter hypermethylation silences cyclooxygenase 2 (COX 2) and regulates growth of human hepatocellular carcinoma cells. Lab. Invest. 84(8), 1050-1059 (2004). (Pubitemid 39025039)
47. Wong CM, Lee Jmf, Ching YP, Jin DY, Ng IOL. Genetic and epigenetic alterations of DLC 1 gene in hepatocellular carcinoma. Cancer Res. 63(22), 7646-7651 (2003). (Pubitemid 37466690)
48. Wong IHN, Lo YMD, Zhang J et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71-73 (1999). (Pubitemid 29062959)
49. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus-DNA sequences in cellular DNA of human hepatocellular-carcinoma. Nature 286(5772), 533-535 (1980). (Pubitemid 10017698)
50. Murakami Y, Saigo K, Takashima H et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54(8), 1162-1168 (2005). (Pubitemid 41025914)
51. Minami M, Daimon Y, Mori K et al. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24(27), 4340-4348 (2005). (Pubitemid 40961757)
52. Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a Cyclin A gene in a hepatocellular-carcinoma. Nature 343(6258), 555-557 (1990).
53. Feitelson MA, Duan LX. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 150(4), 1141-1157 (1997). (Pubitemid 27152632)
54. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell. Biol. 17(11), 6427-6436 (1997). (Pubitemid 27451188)
55. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus x protein inhibits transforming growth factor b-induced apoptosis through the activation of phosphatidylinositol 3 kinase pathway. J. Biol. Chem. 275(33), 25858-25864 (2000).
56. Balsano C, Avantaggiati ML, Natoli G et al. Full-length and truncated versions of the hepatitis B virus (HBV) x protein (px) transactivate the cMyc protooncogene at the transcriptional level. Biochem. Biophys. Res. Commun. 176(3), 985-992 (1991).
57. Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene c jun by the x protein of hepatitis B virus. Virology 192(1), 346-350 (1993).
58. Chirillo P, Falco M, Puri Pl et al. Hepatitis B virus px activates NF kappa β-dependent transcription through a Raf-independent pathway. J. Virol. 70(1), 641-646 (1996). (Pubitemid 126508839)
59. Seto E, Mitchell PJ, Yen TSB. Transactivation by the hepatitis B virus-x protein depends on AP 2 and other transcription factors. Nature 344(6261), 72-74 (1990).
60. Lee JO, Kwun HJ, Jung JK, Choi KH, Min DS, Jang KL. Hepatitis B virus x protein represses E cadherin expression via activation of DNA methyltransferase 1 Oncogene 24(44), 6617-6625 (2005). (Pubitemid 41486792)
61. Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA. Epigenetic repression of E cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene doi: 101038/onc.2011255 (2011) (Epub ahead of print).
62. Lee YH, Yun YD. Hbx protein of hepatitis B virus activates JAK1-STAT signaling. J. Biol. Chem. 273(39), 25510-25515 (1998).
63. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex-formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA 91(22), 10350-10354 (1994). (Pubitemid 24328994)
64. Park US, Park SK, Lee YI, Park JG, Lee YI. Hepatitis B virus-x protein upregulates the expression of p21(waf1/cip1) and prolongs g1 -> s transition via a p53-independent pathway in human hepatoma cells. Oncogene 19(30), 3384-3394 (2000). (Pubitemid 30479333)
65. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus x protein is essential for the activation of wnt/b catenin signaling in hepatoma cells. Hepatology 39(6), 1683-1693 (2004).
66. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-x protein activates a phosphatidylinositol 3 kinase-dependent survival signaling cascade. J. Biol. Chem. 276(20), 16969-16977 (2001).
67. Bader AG, Kang SY, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5(12), 921-929 (2005). (Pubitemid 41766781)
68. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3 kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006). (Pubitemid 44100518)
69. Vivanco I, Sawyers CL. The phosphatidylinositol 3 kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002) (Pubitemid 37328931)
70. Yap TA, Garrett MD, Walton MI, Raynaud F, De Bono JS, Workman P. Targeting the PI3K-AKT-mTor pathway. Progress, pitfalls, and promises. Curr. Opin Pharmacol. 8(4), 393-412 (2008).
71. Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell. Signal. 21(6), 827-835 (2009).
72. Mamane Y, Petroulakis E, Lebacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 25(48), 6416-6422 (2006).
73. Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, Ward SG. Evidence that SHIP 1 contributes to phosphatidylinositol 3,4,5 trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3 kinase effectors. J. Immunol. 169(10), 5441-5450 (2002). (Pubitemid 35291641)
74. Miao BC, Skidan I, Yang JS et al. Small molecule inhibition of phosphatidylinositol- 3,4,5 triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl Acad. Sci. USA 107(46), 20126-20131 (2010).
75. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008).
76. Samuels Y, Wang ZH, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554-554 (2004).
77. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347-351 (2007). (Pubitemid 46328493)
78. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007). (Pubitemid 350134889)
79. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3 kinase a (p85 a-p110 aα) in cell survival and for phosphatidylinositol 3 kinase α (p85 α-p110 β) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19(44), 5083-5090 (2000).
80. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2), 104-107 (2007). (Pubitemid 47199129)
81. Li Y, Tian Z, Fu B, Xin Y. LOH on 10q233 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. Ann. Oncol. 19, 43-43 (2008).
82. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations. The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184-192 (2006). (Pubitemid 43292562)
83. Feilotter HE, Coulon V, McVeigh Jl et al. Analysis of the 10q23 chromosomal rgion and the PTEN gene in human sporadic breast carcinoma. Br. J. Cancer 79(5-6), 718-723 (1999). (Pubitemid 29082095)
84. Gray IC, Stewart LMD, Phillips SMA et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 78(10), 1296-1300 (1998). (Pubitemid 28495240)
85. Bellacosa A, Defeo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64(4), 280-285 (1995).
86. Bleeker FE, Felicioni L, Buttitta F et al. AKT1(E17K) in human solid tumours. Oncogene 27(42), 5648-5650 (2008).
87. Malanga D, Scrima M, De Marco C et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7(5), 665-669 (2008). (Pubitemid 351499006)
88. Sahin F, Kannangai R, Adegbola O, Wang JZ, Su G, Torbenson M. mTOR and P70S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 10(24), 8421-8425 (2004). (Pubitemid 40053405)
89. Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6), 1972-1983 (2008).
90. Sieghart W, Fuereder T, Schmid K et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83(4), 425-432 (2007). (Pubitemid 46667846)
91. Zhou LD, Huang Y, Li JD, Wang ZM. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol. 27(2), 255-261 (2010).
92. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u PA and c Met mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87(5), 644-649 (2000). (Pubitemid 30620405)
93. Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, Larochelle WJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 7(11), 1513-1523 (1996). (Pubitemid 26378346)
94. Tovar V, Alsinet C, Villanueva A et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF 1R blockage. J. Hepatol. 52(4), 550-559 (2010).
95. Mannova P, Beretta L. Activation of the N Ras-PI3K-AKT-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J. Virol. 79(14), 8742-8749 (2005). (Pubitemid 40934785)
96. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol. 45(6), 786-796 (2006). (Pubitemid 44646687)
97. Bader AG, Kang SY, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA 103(5), 1475-1479 (2006). (Pubitemid 43191190)
98. Samuels Y, Diaz LA, Schmidt-Kittler O et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6), 561-573 (2005). (Pubitemid 40799249)
99. Zhao JJ, Liu ZN, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110 aα and p110 β phosphatidylinositol 3 kinases in human mammary epithelial cells. Proc. Natl Acad. Sci. USA 102(51), 18443-18448 (2005). (Pubitemid 43011245)
100. Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3 kinase. Cancer Chemother. Pharmacol. 44(6), 491-497 (1999). (Pubitemid 29501019)
101. Hu LM, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3 kinase inhibitor (LY294002). Clin. Cancer Res. 6(3), 880-886 (2000). (Pubitemid 30159344)
102. Amaravadi R, Thompson CB. The survival kinases AKT and PIM as potential pharmacological targets. J. Clin. Invest. 115(10), 2618-2624 (2005). (Pubitemid 41434384)
103. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3 K family defines a role for p110 aα in insulin signaling. Cell 125(4), 733-747 (2006).
104. Marone R, Cmijanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3 kinase - moving towards therapy. Iochim. Biophys. Acta 1784(1), 159-185 (2008).
105. Fan QW, Knight ZA, Goldenberg Dd et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5), 341-349 (2006). (Pubitemid 43668732)
106. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c Myc-driven apoptosis via PIK3CA/AKT/ mTOR and COX 2 in a mouse model of human liver cancer. Gastroenterology 135(4), 1322-1332 (2008).
107. Flinn IW, Byrd JC, Furman RR et al. Preliminary evidence of clinical activity in a Phase I study of CAL 101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3 kinase (P13K), in patients with select hematologic malignancies. J. Clin. Oncol. 27(15), 3543 (2009).
108. Jimeno A, Hong DS, Hecker S et al. Phase I trial of PX 866, a novel phosphoinositide- 3 kinase (PI 3K) inhibitor. J. Clin. Oncol. 27(15), 3542 (2009).
109. Wagner AJ, Von Hoff DH, Lorusso PM et al. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC 0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 27(15), 3501 (2009).
110. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J. D 21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer 33(3), 442-446 (1997). (Pubitemid 27168072)
111. Van Ummersen L, Binger K, Volkman J et al. A Phase I trial of perifosine (NSC 639966) on a loading dose/ maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 10(22), 7450-7456 (2004). (Pubitemid 39557506)
112. Campos LT, Nemunaitis J, Stephenson J et al. Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J. Clin. Oncol. 27(15), e15505 (2009).
113. Tolcher AW, Yap TA, Fearen I et al. A Phase I study of MK 2206, an oral potent allosteric AKT inhibitor (AKTi), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 27(15), 3503 (2009).
114. Chen KF, Chen HL, Tai WT et al. Activation of PI3K/AKT signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells J. Pharmacol. Exp. Ther. 337(1), 155-161 (2011).
115. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY 22,989), a new antifungal antibiotic .1 Taxonomy of producing streptomycete and isolation of active principle. J. Antibiot. (Tokyo) 28(10), 721-726 (1975).
116. Yatscoff RW, Legatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther. Drug Monit. 15(6), 478-482 (1993). (Pubitemid 23347236)
117. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671-688 (2006). (Pubitemid 44151605)
118. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12(1), 9-22 (2007). (Pubitemid 47001784)
119. Hay N. The AKT-mTOR tango and its relevance to cancer. Cancer Cell 8(3), 179-183 (2005). (Pubitemid 41317589)
120. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6(9), 729-734 (2006). (Pubitemid 44286004)
121. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI 779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004). (Pubitemid 41103603)
122. Blaszkowsky LS, Abrams TA, Miksad RA et al. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). ASCO Annual Meeting, Chicago, IL, USA, 4-8 June (2010).
123. Kelley RK, Nimeiri HS, Vergo MT et al. A Phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC). Gastrointestinal Cancer Symposium. San Francisco, CA, 20-22 January 2011
124. Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A decade of experience using mTOR inhibitors in liver transplantation. J. Transplant. 2011, 913094 (2011).
125. Levy G, Schmidli H, Punch J et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36 month results. Liver Transplant. 12(11), 1640-1648 (2006). (Pubitemid 44742543)
126. Roberts RJ, Wells AC, Unitt E et al. Sirolimus-induced pneumonitis following liver transplantation. Liver Transplant. 13(6), 853-856 (2007). (Pubitemid 46939439)
127. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78(2), 264-268 (2004).
128. Toso C, Meeberg GA, Bigam Dl et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83(9), 1162-1168 (2007). (Pubitemid 46743675)
129. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant. 10(10), 1301-1311 (2004). (Pubitemid 39406087)
130. Schnitzbauer AA, Zuelke C, Graeb C et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 10, 190 (2010).
131. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005). (Pubitemid 40262113)
132. Shah OJ, Wang ZY, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14(18), 1650-1656 (2004). (Pubitemid 39239362)
133. Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol. 7(2), 371-383 (2009).
134. Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J. Biol. Chem. 284(12), 8023-8032 (2009).
135. Chresta CM, Davies BR, Hickson I et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70(1), 288-298 (2010).
136. Zhao JJ, Cheng HL, Jia SD et al. The p110 aα isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl Acad. Sci. USA 103(44), 16296-16300 (2006). (Pubitemid 44715190)
137. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110 β isoform of phosphoinositide 3 kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 γ. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008). (Pubitemid 351904749)
138. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 66(3), 1500-1508 (2006). (Pubitemid 43259931)
139. Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5(1), 139-151 (2008).
140. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP BEZ235, a new orally available dual phosphatidylinositol 3 kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7(7), 1851-1863 (2008).
141. Serra V, Markman B, Scaltriti M et al. NVP BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68(19), 8022-8030 (2008).
142. Buchbinder EI, Cohen MB, Jung DE et al. In vitro efficacy of the dual PI3 Kinase/ mTOR inhibitor NVP BEZ235 in hepatocellular carcinoma. Molecular Cancer Therapeutics. 8(12 Suppl. 1), C60 (2009).
143. Liu PX, Cheng HL, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3 kinase pathway in cancer. Nat. Rev. Drug Discov. 8(8), 627-644 (2009).
144. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin.59(2), 111-137 (2009).
145. Chiorean EG, Mahadevan D, Harris WB et al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J. Clin. Oncol. 27(15), 2558 (2009).
146. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-AKT cross-talk. J. Biol. Chem. 277(34), 31099-31106 (2002). (Pubitemid 34970815)
147. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118(9), 3065-3074 (2008).
148. Raynaud FI, Eccles S, Clarke PA et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3 kinases. Cancer Res. 67(12), 5840-5850 (2007). (Pubitemid 46985018)
149. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6), 747-759 (2005). (Pubitemid 40568794)
150. Mondesire WH, Jian WG, Zhang Hx et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10(20), 7031-7042 (2004). (Pubitemid 39383055)
151. Wu LC, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI 779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65(7), 2825-2831 (2005). (Pubitemid 40490085)
152. Yan HJ, Frost P, Shi YJ et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66(4), 2305-2313 (2006).
153. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RWC, Poon RTP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 273(2), 201-209 (2009).
154. Piguet AC, Semela D, Keogh A et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol. 49(1), 78-87 (2008).
155. Bu XX, Le C, Jia FQ et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol. Ther. 7(3), 392-396 (2008). (Pubitemid 351847053)
156. Patil MA, Chua MS, Pan KH et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24(23), 3737-3747 (2005). (Pubitemid 40826873)
157. Tung CY, Jen CH, Hsu MT, Wang HW, Lin CH. A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets. BMC Genomics 10, (2009).
158. Nowak AK, Chow PKH, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur. J. Cancer 40(10), 1474-1484 (2004). (Pubitemid 38757734)
159. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94(4), 492-499 (2001).
160. Chao Y, Chan WK, Birkhofer MJ et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer 78(1), 34-39 (1998). (Pubitemid 28276766)
161. Hebbar M, Ernst O, Cattan S et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 70(2), 154-158 (2006). (Pubitemid 43760342)
162. Szebeni J, Alving CR, Savay S et al. Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions. Int. Immunopharmacol. 1(4), 721-735 (2001). (Pubitemid 32206533)
163. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor El. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590-1598 (2001). (Pubitemid 32778603)
164. Green MR, Manikhas GM, Orlov S et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17(8), 1263-1268 (2006). (Pubitemid 44288216)
165. Zhou Q, Ching AK, Leung WK et al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int. J. Oncol. 38(3), 721-731 (2011).
166. Blum JL, Savin MA, Edelman G et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 7(11), 850-856 (2007).
167. Marimpietri D, Brignole C, Nico B et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin. Cancer Res. 13(13), 3977-3988 (2007). (Pubitemid 47037606)
168. Campostrini N, Marimpietri D, Totolo A et al. Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. Proteomics 6(15), 4420-4431 (2006). (Pubitemid 44277043)
169. Shafer A, Zhou CX, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int. J. Cancer 126(5), 1144-1154 (2010).
170. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2), 333-339 (2007). (Pubitemid 46158128)
171. Sessa C, Tosi D, Vigano L et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK 8669) with weekly paclitaxel. Ann. Oncol. 21(6), 1315-1322 (2010).
172. Ribatti D, Nico B, Mangieri D et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histopathol. 22(3), 285-289 (2007). (Pubitemid 46117114)
173. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors. Cancer Biol. Ther. 7(2), 307-315 (2008).
174. Ito Y, Sasaki Y, Harimoto M et al. Activation of mitogen-activated protein kinase extracellular signal-regulated protein kinase in human hepatocellular carcinoma. Hepatology 26(4), 1002-1002 (1997).
175. Schmidt CM, Mckillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236(1), 54-58 (1997). (Pubitemid 27341838)
176. Saini KS, Piccart-Gebhart MJ. Dual targeting of the PI3K and MAPK pathways in breast cancer. Asia-Pacific Journal of Oncology & Hematology 2(2), 13-17(2010).
177. Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118(9), 3051-3064 (2008).
178. Lasithiotakis KG, Sinnberg TW, Schittek B et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128(8), 2013-2023 (2008). (Pubitemid 352001225)
179. Liu L, Cao YC, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res. 66(24), 11851-11858 (2006). (Pubitemid 46094197)
180. Wang Z, Zhou J, Fan J et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 14(16), 5124-5130 (2008).
181. Shinohara ET, Cao C, Niermann K et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24(35), 5414-5422 (2005). (Pubitemid 43080085)
182. Albert JM, Kim KW, Cao C, Lu B. Targeting the AKT/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5(5), 1183-1189 (2006). (Pubitemid 43881310)
183. Manegold PC, Paringer C, Kulka U et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 14(3), 892-900 (2008). (Pubitemid 351231174)
184. Pang RWC, Poon RTP. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72, 30-44 (2007). (Pubitemid 350256663)
185. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48(4), 1312-1327 (2008).
186. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies J. Gastroenterol. 46(3), 289-296 (2011).
187. Buontempo F, Ersahin T, Missiroli S et al. Inhibition of AKT signaling in hepatoma cells induces apoptotic cell death independent of AKT activation status. Invest. New Drugs (2010) (Epub ahead of print).
188. Schoniger-Hekele M, Muller C. Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment. Pharmacol. Ther. 32(6), 763-768 (2010).
189. Na GC, Timasheff SN. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 19(7), 1355-1365 (1980). (Pubitemid 10038932)
190. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63(8), 803-843 (2003). (Pubitemid 36432084)
191. Sandler AB. Chemotherapy for small cell lung cancer. Semin. Oncol. 30(1), 9-25 (2003). (Pubitemid 36254671)
192. Jassem J, Kosmidis P, Ramlau R et al. Oral vinorelbine in combination with cisplatin. A novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. 14(11), 1634-1639 (2003). (Pubitemid 37455812)
193. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Semin. Oncol. 30(2), 6-10 (2003). (Pubitemid 36506283)
194. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther. 2(5), 427-436 (2003).
195. Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, Wilson L. Interaction of the anitumor compound cryptophycin 52 with tubulin. Biochemistry 39(46), 14121-14127 (2000).
196. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Cancer Res. 61(3), 1013-1021 (2001). (Pubitemid 32174419)
197. Loganzo F, Discafani CM, Annable T et al. HTI 286, a synthetic analog of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63(8), 1838-1845 (2003). (Pubitemid 36460846)
198. Hamel E. Natural-products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin a, dolastatin 10 and dolastatin 15 and halichondrin B. Pharmacol. Ther. 55(1), 31-51 (1992). (Pubitemid 23018631)
199. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J. Cell Biol. 94(3), 688-696 (1982). (Pubitemid 13241201)
200. Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38, S13-S19 (2002). (Pubitemid 36034219)
201. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325-2333 (1995).
202. Honore S, Kamath K, Braguer D, Wilson L, Briand C, Jordan MA. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol. Cancer Ther. 2(12), 1303-1311 (2003).
203. Skoufias DA, Wilson L. Mechanism of inhibition of microtubule polymerization by colchicines: inhibitory potencies of unliganded colchicine and tubulin colchicine complexes. Biochemistry 31(3), 738-746 (1992).
204. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Experimental Pathology 83(1), 21-38 (2002). (Pubitemid 34638944)
205. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2 methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23(2), 165-172 (2003).
206. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 57(15), 3208-3213 (1997). (Pubitemid 27351737)
207. Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl Acad. Sci. USA 94(20), 10560-10564 (1997). (Pubitemid 27430773)
208. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4(4), 253-265 (2004). (Pubitemid 38525281)
209. Martelli AM, Chiarini F, Evangelisti C et al. The phosphatidylinositol 3 kinase/AKT/ mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol. Histopathol. 25(5), 669-680 (2010).